OmniRayn
← All repurposing reports
S2 (505(b)(2))

Osteoarthritis

Known, approved drugs ranked as repurposing candidates for Osteoarthritis — each scored for reversal of the disease expression signature, cytotoxicity-filtered, and prioritized by clinical maturity. Computational, pending wet-lab.

Preview. Candidate identities are shown below. The full ranking, quantified reversal scores, per-candidate mechanistic rationale, ClinicalTrials.gov whitespace detail, and structure-function intelligence are included with the dossier.

Top candidates preview

  1. 1methylene blueApproved
  2. 2artesunateApproved
  3. 3fulvestrantApproved
  4. 4perhexilineApproved
  5. 5sulconazoleApproved
  6. 6teniposideApproved
  7. 7valdecoxibApproved
  8. 8papaverineApproved

Full dossier — 145 cytotox-screened candidates

Quantified reversal ranking · mechanistic rationale · CT.gov whitespace · S2 (505(b)(2)) regulatory framing · structure-function intelligence.

Acquire dossier — $3,950